Dormant
CLPT · ClearPoint Neuro, Inc.
Last analysed ·
Resolved Graded and closed 2026-07-17 at low conviction — the published kill line fired. Coverage continued after the close; the read below is dated 2026-09-19 and is not part of the scored record.
Current thesis
Picks-and-shovels delivery play on CNS gene therapy: ClearPoint's SmartFlow cannula and MRI navigation are the standard route to the brain for uniQure's AMT-130 Huntington's BLA (soft Q3-2026 window). The June re-rate held near $18.72 (7/02) but the theme has cooled to maturing, with no dated catalyst inside 30 days except the ~mid-August Q2 print. A base-watch, not a momentum entry.
Kill line
A weekly close below $16 loses the post-catalyst breakout shelf (6/18 gap close $16.81) and unwinds the June re-rate; secondary breaks: the AMT-130 Huntington's BLA slips the Q3-2026 window or draws an FDA refuse-to-file, or FY2026 revenue guide is cut below the $52M floor.
Pick status
Invalidated resolved published kill line fired How this is scored →Latest analysis and events for CLPT —
As of 19 September 2026, the latest FrontierPicks analysis for ClearPoint Neuro, Inc. (CLPT): Picks-and-shovels delivery play on CNS gene therapy: ClearPoint's SmartFlow cannula and MRI navigation are the standard route to the brain for uniQure's AMT-130 Huntington's BLA (soft Q3-2026 window). The June re-rate held near $18.72 (7/02) but the theme has cooled to maturing, with no dated catalyst inside 30 days except the ~mid-August Q2 print. A base-watch, not a momentum entry.
Kill line: A weekly close below $16 loses the post-catalyst breakout shelf (6/18 gap close $16.81) and unwinds the June re-rate; secondary breaks: the AMT-130 Huntington's BLA slips the Q3-2026 window or draws an FDA refuse-to-file, or FY2026 revenue guide is cut below the $52M floor.
Next dated event on file: — catalyst in 10d.
Current Thesis
ClearPoint Neuro’s gene-therapy delivery story now requires a recovery: the forthcoming AMT-130 data must be followed by a close above $15.39 before a daily close below $13.83 ends that case. Those are public reference closes from 2026-08-21 and 2026-09-18, respectively. This is a separate recovery hypothesis; the earlier June-breakout thesis has already failed its published $16 weekly-close condition.
As a price-supported June breakout, the narrative is dead — the 2026-09-18 close of $13.83 remains below that threshold despite uniQure’s 2026-09-02 biologics license application (BLA) submission for AMT-130. The underlying delivery opportunity remains conditional on partner approval and commercial procedures. UniQure’s investor page still lists the September filing as its latest release; it does not establish approval or commercial delivery revenue. uniQure investor updates
Bullish and bearish views on ClearPoint Neuro, Inc.
The model's bull view on ClearPoint Neuro, Inc. (CLPT), in brief: The partner reached filing. uniQure announced its AMT-130 BLA submission on 2026-09-02. The recovery hypothesis rests on further clinical progress attracting demand for ClearPoint’s delivery exposure; a daily close below the 2026-09-18 reference close of $13.83 invalidates it.… The bear view: Delivery revenue contracted before commercialization. Both cases follow in full.
Bull Case
- The partner reached filing. uniQure announced its AMT-130 BLA submission on 2026-09-02. The recovery hypothesis rests on further clinical progress attracting demand for ClearPoint’s delivery exposure; a daily close below the 2026-09-18 reference close of $13.83 invalidates it. uniQure investor updates
- Management expects segment recovery. ClearPoint’s 2026-08-03 release expected new laboratory services to restore biologics and drug delivery growth in the third quarter. Flat or declining year-over-year segment revenue at the next results would contradict that expectation. ClearPoint second-quarter results
Bear Case
- Delivery revenue contracted before commercialization. ClearPoint reported second-quarter 2026 biologics and drug delivery revenue of $4.0 million, down 15% year over year. Its 2026-08-03 release attributed the decline to lower shipments supporting trial initiations and identified a prior-year customer order that did not recur; that comparison alone does not establish a persistent slowdown. ClearPoint second-quarter results
- Spending exceeds current revenue. The 2026-08-03 release reported second-quarter revenue growth of 18%, operating expense growth of 51% to $17.0 million, and full-year revenue guidance of $48–52 million. First-half operating cash use was $15.0 million. These figures establish financing exposure without establishing when financing occurs. ClearPoint second-quarter results
Setup & Price Structure
The adjusted daily series records a $13.83 close on 2026-09-18, a three-month decline of 18.9%, and a 53.3% distance below the $29.60 trailing-year high. The 14-day relative strength index (RSI) was 27.0. These measured readings document weakness; they do not establish a reversal.
The $15.39 close recorded on 2026-08-21 is the recovery checkpoint. The $13.83 reference close is the prospective failure threshold for this narrowly defined recovery case, not an established support shelf. No moving-average value, current short-interest figure, or current insider-sale disclosure is available in the cited evidence. The Benzinga coverage supplied for 2026-06-17 and 2026-06-18 documents a historical attention cluster; that sample is too small and too old to establish current crowding.
Catalyst Calendar (next 30 days)
- ~2026-09-30, window endpoint only: uniQure’s 2026-09-02 disclosure guided to a four-year AMT-130 analysis before the end of the third quarter, covering 24 patients with a 2026-06-30 data cutoff. Its 2026-07-29 update also specified September. No exact presentation day is confirmed; absence of the analysis by 2026-09-30 breaks the stated near-term catalyst premise. uniQure July update
As checked on 2026-09-19, ClearPoint’s investor calendar lists no upcoming events. There is consequently no confirmed company event date to substitute for the partner’s disclosure window. ClearPoint investor calendar
What Would Change Our Mind
Failure to preserve the latest reference close would end the recovery hypothesis: a daily close below $13.83, the 2026-09-18 adjusted close, is the observable break. Publication of the promised analysis followed by a daily close above $15.39 before that break would satisfy the defined recovery case. It would not, by itself, establish commercial adoption or restore the failed $16 June-breakout condition.
The clinical and commercial questions remain distinct. The forthcoming analysis concerns 24 patients according to uniQure’s September guidance; that sample cannot establish commercial procedure demand. ClearPoint’s next reported biologics and drug delivery revenue can separately test management’s 2026-08-03 expectation of renewed third-quarter growth.
Correlation Notes
This is a single-company delivery thesis, with uniQure’s 2026-09-02 filing providing the identifiable partner exposure. No matched return series is available to quantify correlation with uniQure or a broader biotechnology group. ClearPoint’s 2026-09-18 close below its historical $16 threshold demonstrates that partner regulatory progress and recovery of the earlier price structure are separate outcomes.
Notes
- Trades as a uniQure delivery proxy: AMT-130 regulatory and data headlines move the tape more than ClearPoint's own reported numbers.
- S-3 shelf on file; the Oberland note facility carries $25M and $50M tranches drawable before 2026-12-31 — a standing financing overhang.
- A resale prospectus covers up to 1,312,570 shares issued to former IRRAS holders (merger closed 2025-11-20), effective 2026-01-14 — supply requiring no company action.
- FY2026 revenue guidance is $48–52M as of 2026-08-03, cut from $52–56M; any model built on the older range is stale.
- Q2 2026 opex included the IRRAS acquisition and the CAL Torrey Pines facility taken over in July 2026; the cost base is not comparable to prior-year quarters.
- The $500M 'Essential. Everywhere.' ambition ($200M four pillars + $300M commercial drug delivery) carries no company-stated target year.
Related · shared themes
TXG
10x Genomics, Inc.
10x Genomics' Atera recovery now needs deliveries and revenue confirmation after clearing its earlier price hurdle. Approximately 40 second-half 2026 shipments and full-year revenue of $610–630 million would substantiate the case before a weekly close below $58.57 invalidates the structure.
APGE
Apogee Therapeutics, Inc.
Apogee Therapeutics’ $135.11-per-share cash-acquisition thesis resolved with AbbVie’s completion on 2026-09-03. The 2026-09-14 Form 15 advances administrative closure, leaving no unresolved APGE acquisition catalyst.
ATAI
AtaiBeckley Inc.
AtaiBeckley's Lilly acquisition thesis resolved with completion on 2026-09-11, ending the pending-merger case. Remaining contingent payments depend on disclosed clinical and regulatory milestones; Nasdaq suspended ATAI effective 2026-09-14.
ITGR
Integer Holdings Corporation
Integer Holdings Corporation’s $127.00 cash acquisition by KKR remains a completion thesis, strengthened by the 2026-09-03 merger proxy. Completion by year-end 2026 would settle the case; a daily close below $118 invalidates it.
See also · stocks to watch